MiNK Therapeutics, Inc.
INKT
$14.72
-$0.44-2.90%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -38.95% | -41.95% | -22.19% | -14.03% | -4.69% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -44.08% | -43.36% | -44.23% | -37.82% | -28.99% |
| Operating Income | 44.08% | 43.36% | 44.23% | 37.82% | 28.99% |
| Income Before Tax | 52.69% | 51.98% | 44.36% | 34.23% | 20.52% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 52.69% | 51.98% | 44.36% | 34.23% | 20.52% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 52.69% | 51.98% | 44.36% | 34.23% | 20.52% |
| EBIT | 44.08% | 43.36% | 44.23% | 37.82% | 28.99% |
| EBITDA | 44.79% | 44.03% | 44.66% | 38.20% | 29.38% |
| EPS Basic | 58.01% | 55.52% | 46.74% | 36.06% | 22.20% |
| Normalized Basic EPS | 50.93% | 48.42% | 46.25% | 35.63% | 29.80% |
| EPS Diluted | 47.54% | 46.19% | 46.93% | 36.28% | 22.46% |
| Normalized Diluted EPS | 50.93% | 48.42% | 46.25% | 35.63% | 29.80% |
| Average Basic Shares Outstanding | 12.88% | 9.79% | 6.73% | 3.61% | 2.19% |
| Average Diluted Shares Outstanding | 12.88% | 9.79% | 6.73% | 3.61% | 2.19% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |